

CURRICULUM VITAE

Personal Information

Name and Forename: Khalid **BAJOU**
Place and date of birth: Casablanca, October 12, 1965
Nationality: Belgian
Marital status: Married

Contact Information

Professional address: Department of Applied Biology/Biotechnology Program
College of Sciences
University of Sharjah
Sharjah, P.O.Box: 27272
United Arab Emirates
Work phone: (971) 6505-3832
E-mail: kbajou@sharjah.ac.ae

ACADEMIC DEGREES:

Ph.D in Science University of Liège, Liege, Belgium. (Supervisor, Professor J.M. Foidart)
Dissertation title: Role of Plasminogen Activator Inhibitor-1 in tumor
invasion and angiogenesis. **October 25, 2001.**

Master of Molecular and Cellular Biology
University of Liège, Liege, Belgium. **September 1990 – June 1992.**

Bachelor of Science (zoology)
University of Hassan II, Casablanca - Morocco **September 1986 – June 1990**

ACADEMIC RANKS and EMPLOYMENT HISTORY:

September 2015 - Present: Assistant Professor in the Department of Applied Biology. Faculty of Science, University of Sharjah, Sharjah, UAE.

July 2007 – July 2015: Assistant Professor in the Interdisciplinary Cluster for Applied Genoproteomics (GIGA) Research Center at the University of Liege, Liege, Belgium.

November 2002 – Jun 2007: Postdoctoral fellow in the Division of Hematology-Oncology, Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles.

October 2001 – October 2002 : Postdoctoral fellow in the Division of Tumor and Developmental Biology, Department of Clinical Sciences, University of Liège, Liege, Belgium.

September 1995 – September 2001: Ph.D. student under a supervision of Prof. Jean Michel Foidart, Division of Tumor and Developmental Biology, Department of Clinical Sciences, University of Liège, Liege, Belgium.

October 1992 – August 1995: Researcher position under a supervision of Prof. Jose Remacle, Laboratory of Biochemistry and Cellular Biology, Faculty of Sciences, University of Namur, Namur, Belgium.

Citation Record in:

Google Scholar Database: 01/03/18

Citations: 3306

h-index: 21

Scopus Database: 01/03/18

Citations: 2482 total citations by 1895 documents

h-index: 22

Scopus link:

<https://www.scopus.com/authid/detail.uri?authorId=6601960766>

Google scholar link:

<https://scholar.google.ae/citations?user=JMqDy6oAAAAJ&hl=en>

Researchgate link

https://www.researchgate.net/profile/Khalid_Bajou

AWARDS, FELLOWSHIPS and GRANTS.

Van Beirs Prize 2002, Liege, Belgium.

Lions Club Prize 2002, Liege, Belgium.

Adolphe Wetrems Prize 2001 by the Royal Academy of Science, Literature and Art of Belgium, Brussels, Belgium.

Alvarenga de Piauhy Prize 2001 by the Royal Academy of Medicine of Belgium, Brussels, Belgium.

Travel award by AACR-AstraZeneca, American Association for Cancer Research, 97th Annual Meeting, Washington DC: April 1-5, 2006.

Travel award by Gorgon Research Conferences, Plasminogen Activation and Extracellular Proteolysis, Ventura, CA: February 8-13, 2004.

Best poster prize by the American Association for Cancer Research (travel Grand Award) June 14-18, Nyborg, Denmark, 1998.

Travel Fellowship awarded by “Agathon De Potter Fondation”, the Royal Academy of Science, Literature and Art of Belgium, Brussels, Belgium, 2002.

Post-doc Fellowship awarded by Rose and Jean Hoguet Foundation, Brussels, Belgium, 2002-2003

Post-doc Fellowship awarded by the “CENTRE ANTICANCEREUX” Liège, Belgium, 2002

Post-doc Fellowship awarded by the “KANKEROLOGISCHE STICHTING ST-MICHIEL V.Z.W.” Foundation, Brussels, Belgium, 2002.

Post-doc Fellowship awarded by the Rotary International District 1630, Belgium, 2002.

Post-doc Fellowship awarded by the “M^r et M^m F. Braconier-Lamarche”, Liege, Belgium, 2002.

Competitive Grant awarded by the University of Sharjah, Sharjah, UAE, January 2017-December 2019.

Seed Grant awarded by the University of Sharjah, Sharjah, UAE, September 2016 - August 2017.

Research Grant awarded by the Belgian Federal Science Policy, Brussels, Belgium, July 2007 – Jun 2009.

Research Grant for Career Development awarded by the Children's Hospital Los Angeles, University of Southern California, Los Angeles, July 2003 – Jun 2005.

Ph.D Fellowship awarded by the “Fonds National de la Recherche Scientifique” (FNRS), Belgium. October 1997 – September 2001:

Grant awarded by the “Fondation Léon Frédéricq” 1999, Liège, Belgium.

Grant awarded by the “Association Sportive Contre le Cancer” 1996, Brussels, Belgium.

Ph.D Fellowship awarded by the “Centre Anticancereux” Liège, Belgium. October 1996 – September 1997:

PATENT:

Struman,I., Martial,J., **Bajou,K.**, D'Amico,S.

A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone(GH) - placental lactogen (PL)-family protein., 2011, Europe. Application # PCT/EP2011/052293
2013, USA Application #20130035289

RESEARCH AREAS:

Cancer biology: angiogenesis, metastasis and tumor animal models.

Serine proteases.

Thrombosis and thrombolysis.

TEACHING EXPERIENCES:

University of Sharjah, Sharjah, United Arab Emirate.

Undergraduate courses:

General Biology I (1450 101)
General Biochemistry (1450 351)
Protein Biotechnology & Engineering (1450 453)
Cancer Biology (Selected Topics in Biotech. A -1450 492A)
Scientific Writing and Presentation (1450 391)
Cell Biology (1450 251)
Immunology & Serology (1450 333)
Seminar (1450 491)
Research Project (1450 493)
Field Training (1450 399)

Postgraduate courses:

Advance biochemistry and Molecular Biology (1450 551) (Master degree)

University of Liege, Liege, Belgium

General Biology 2, (Undergraduate)
Cell Structure and Function, (Undergraduate)
Preclinical tumor models (postgraduate and Ph.D. students)

STUDENT SUPERVISION

M.Sc Thesis

Stephanie Herkenne: Caracterisation de la liaison entre la proteine anti-angiogene, la polactine 16K et son partenaire de liaison. University of Liege (2008)

Antoine Dalla Valle: Implication du signalosome uPAR dans les effets anti-angiogène de la prolactin 16K. University of Liege (2011)

Undergraduate project

Natalie Karayan et al., Purification of Plasminogen from human plasma. University of Sharjah (Spring 2015-2016).

Ayecha Saadah et al., Diesel exhaust particles induced lung inflammation and its effect on cancer progression. University of Sharjah (Fall 2016-2017).

Sara Alkaabi et al., Effect of glucose on tumor cells. University of Sharjah (Fall 2016-2017).

Sara Alkathoori et al., Effect of natural products on clot lysis using an in vitro model. University of Sharjah (Spring 2016-2017).

Amirah AbuGhoush et al., Effect of air pollution on cancer progression. University of Sharjah (Spring 2016-2017).

OTHER ACADEMIC ACTIVITIES:

- Manuscript review for British Journal of Cancer, Cancer Research and Frontiers in Experimental Pharmacology and Drug Discovery.
- Invited speaker at the University of Namur, Role of PAI-1 in invasion and tumor angiogenesis. March 11, 2009
- Invited Jury member for Ph.D thesis of Britt VAN DE CRAEN, Species and glycosylation dependency of PAI-1 inhibition, Faculty of Pharmacological Sciences, University of Leuven, Leuven, Belgium, 2011.
- Grant reviewing activity for King Fahad Medical City (KFMC), Ministry of Health, Riyadh.
- Judge for the 10th UOS Annual Graduate Research Forum, University of Sharjah, May 16th, 2016

COMMUNITY SERVICES

College of Sciences:

- Chair of the “Instruments & Laboratories Committee” September 2017- August 2018
- Member of the “College council” September 2015- August 2016; September 2016- August 2017
- Member of the “Instruments & Laboratories Committee” September 2016- August 2017
- Member of the “External Activities and Innovation Committee” September 2015- August 2016

Applied Biology Department:

- Chair of the “Laboratories & Safety committee”, September 2015- August 2016; September 2016- August 2017; September 2017- August 2018.
- Chair of the “College of Sciences Instruments & Laboratories Committee” September 2016- August 2017.
- Member of the “Curriculum Accreditation committee”, September 2015- August 2016; September 2016- August 2017; September 2017- August 2018.
- Member of the “Post-graduate study committee” September 2016- August 2017; September 2017- August 2018.
- Member of the “Student’s Advising & Training committee”, September 2015- August 2016; September 2016- August 2017; September 2017- August 2018.
- Member of the “Conferences & Seminars committee”, September 2015- August 2016; September 2016- August 2017; September 2017- August 2018.

University of Liege:

- Creation and supervision of tumor animal model platform in GIGA research institute, University of Liege (2011-2013)
- Organizer and Chairman of GIGA-Cancer research seminars in GIGA research institute, University of Liege (weekly research presentation for Academic year 2012-2013).
- Organizing committee for a GIGA-Cancer day

SCIENTIFIC SOCIETIES:

- American Association for Cancer Research (active member)
- The International Society on Thrombosis and Haemostasis (regular member)
- International Proteolysis Society (regular member)
- Belgian Association for Cancer Research (regular member)
- The Belgian Society for Cell and Developmental Biology (regular member)

PUBLICATIONS

Book chapters

DeClerck, Y.A., **Bajou, K.**, Laug, W.E., Proteinases and their inhibitors in angiogenesis, in *Anti-Angiogenic Cancer Therapy*, eds. DW Davis, RS Herbst, and JL Abbruzzese, CRC Press, eds Boca Raton, FL, 2007, p 239 – 255.

Michiels, C., Arnould, T., **Bajou, K.**, Géron, I., Remacle, J.
Hypoxia activates endothelial cells to release inflammatory mediators and growth factors, in *Proceedings of the International Summer School: Molecular mechanisms of transcellular signalling from the membrane to the gene*, Pocker & Kwawirtz, eds, verlag Berlin, Heidelberg, 1994, p 251-260.

Publication with peer review

Tlili, A., Fahd Al Mutery, A., Mahfood, M., Kamal Eddine Ahmad Mohamed, W., **Bajou, K.**
Identification of a novel frameshift mutation in the ILDR1 gene in a UAE family, mutations review and phenotype genotype correlation.
PLoS One. 2017 Sep 25; **12**(9):e0185281. doi: 10.1371/journal.pone.0185281. eCollection 2017.
I.F. = 3.226

Herkenne, S., Paques, P., Nivelles, N., Lion, M., **Bajou, K.**, Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.Q.N., Struman, S.
The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis.
Sci. Signal. 2015 Nov 17; **8**(403):ra117
I.F. = 6.279

Bajou, K., Herkenne, S., Thijssen, V.L., D'Amico, S., Nguyen, N.Q.N., Bouché, A., Tabruyn, S., Srahna, M., Carabin, J.V., Nivelles, O., Paques, C., Cornelissen, I., Lion, M., Noel, A., Gils, A., Vinckier, S., Declerck, P.J., Griffioen, A.W., Dewerchin, M., Martial, J.A., Carmeliet, P. and Struman, I.
PAI-1 mediates the anti-angiogenic and pro- fibrinolytic effects of 16K prolactin.
Nat. Med., 2014 jul, **20**, 741-747.
I.F. = 24.302

Amand, M., Erpicum, C., **Bajou, K.**, Cerignoli, F., Blacher, S., Martin, M., Dequiedt, F., Drion, P., Singh, P., Tinatin, Z., Vandereyken, M., Musumeci, L., Mustelin, T., Moutschen, M., Gilles, C., Noel, A. and Rahmouni, S.
DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase
Molecular cancer, 2014, **13**, 1-08
I.F. = 5.130

Bajou, K., Peng, W., Laug, W.E., Maillard, C., Noel, A., Foidart, J.M., Martial, J.A., DeClerck, Y.A.
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
Cancer Cell, 2008, **14**, 324-334
I.F. = 24.962

Jost,M., Maillard,C., Lecomte,J., Lambert,V., Tjwa,M., Blaise,P., Gonzalez,M.A., **Bajou,K.**, Blacher,S., Motte,P., Humblet,C., Defresne,M.P., Thiry,M., Frankenne,F., Gothot,A., Carmeliet,P., Rakic,J.M., Foidart,J.M., Agnès,N.

Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.

Am. J. Pathol., 2007, **171**, 1369-1380

I.F =5.487

Maillard,C., Jost,M., Romer,M.U., Brunner,N., Houard,X., Lejeune,A., Munaut,C., **Bajou,K.**, Melen,L., Dano,K., Carmeliet,P., Fusenig,N.E., Foidart,J.M., Noel,A.,

Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.

Neoplasia, 2005, **7**, 57-66.

I.F =3.850

Masson,V., de la Ballina,L.R., Munaut,C., Wielockx,B., Jost,M., Maillard,C., Blacher,S., **Bajou,K.**, Itoh,T., Itohara,S., Werb,Z., Libert,C., Foidart,J.M., Noel,A.

Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes.

FASEB J., 2005, **19**, 234-6.

I.F =7.064

Bajou,K., Maillard,C., Jost,M., Lijnen,R.H., Gils,A., Declerck,P., Carmeliet,P., Foidart,J.M., Noel,A.

Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for *in vivo* tumoral angiogenesis and growth.

Oncogene, 2004, **23**, 6986-90.

I.F. =6.318

Rakic,J.M., Lambert,V., Munaut,C., **Bajou,K.**, Peyrollier,K., Alvarez-Gonzalez,M.L., Carmeliet,P., Foidart,J.M., Noel,A.

Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.

Invest. Ophthalmol Vis. Sci., 2003, **44**, 1732-1739.

I.F =4.148

Hajitou,A., Grignet,C., Devy,L., Berndt,S., Blacher,S., Deroanne,CF., **Bajou,K.**, Fong,T., Chiang,Y., Foidart,J. M., Noel,A.

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.

FASEB J., 2002, **16**, 1802-4.

I.F. =7.252

Masson,V., Devy,L., Grignet-Debrus,C., Bernt,S., **Bajou,K.**, Blacher,S., Roland,G., Chang, Y., Fong,T., Carmeliet,P., Foidart,J.M., Noel,A.

Mouse aortic ring assay : a new approach of the molecular genetic of angiogenesis. *Biological Procedures Online*, 2002, **4**, 24-31.

I.F. =1.179

Bajou,K., Lewalle,JM., Rodriguez Martinez,C., Soria,C., Lu,H., Noel,A., Foidart,J. M. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression.

Int. J. Cancer., 2002, **100**, 501-506.

I.F. =4.056

Devy,L., Blacher,S., Grignet-Debrus,C., **Bajou,K.**, Masson,V., Gerard,R.D., Gils,A., Carmeliet,G., Carmeliet,P., Declerck,P.J., Noel,A., Foidart,J.M.

The pro-or-anti-angiogenic effect of plasminogen activator inhibitor-1 is dose-dependent. *FASEB J.*, 2002, **16**, 147-54.

I.F. =7.252

Lambert,V., Munaut,C., Noel,A., Franckne,F., **Bajou,K.**, Gerard,R.D., Carmeliet,P., Defresne,M.P., Foidart,J.M., Rakic,J.M.

Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.

FASEB J., 2001, **15**, 1021-1027.

I.F. =7.252

Bajou,K., Masson,V., Gerard,R.D., Schmitt,P.M., Albert,V., Praus,M., Lund,L.R., Frandsen,T.L., Brunner,N., Dano,K., Fusenig,N.E., Weidle,U., Carmeliet,G., Loskutoff,D., Collen,D., Carmeliet,P., Foidart,J.M., Noel,A.

The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. Implications for antiangiogenic strategies.

J.Cell Biol., 2001, **152**, 777-784.

I.F. = 12.915

Bajou,K., Noel,A., Gerard,R.D., Masson,V., Brunner,N., Holst-Hansen,C., Skobe,M., Fusenig,N.E., Carmeliet,P., Collen,D., Foidart,J.M.

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

Nat.Med., 1998, **4**, 923-928.

I.F. = 28.114

Hajitou,A., Baramova,E.N., **Bajou,K.**, Noe,V., Bruyneel,E., Mareel,M., Collette,J., Foidart,J.M., Calberg-Bacq,C.M.

FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells. *Oncogene*, 1998, **17**, 2059-2071.

I.F. = 5.979

Lewalle,J.M., Cataldo,D., **Bajou,K.**, Lambert,C.A., Foidart,J.M.
Endothelial cell intracellular Ca²⁺ concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migration.
Clin. Exp. Metastasis, 1998, **16**, 21-29.
I.F. = 2.080

Devy,L., Noel,A., Baramova,E., **Bajou,K.**, Trentesaux,C., Jardillier,J.C., Foidart,J.M., Jeannesson,P.
Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells.
Biochem. Biophys. Res. Commun., 1997, **238**, 842-846.
I.F. = 2.935

Baramova,E.N., **Bajou,K.**, Remacle,A., L'Hoir,C., Krell,H.W., Weidle,U.H., Noel,A., Foidart,J.M.
Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation.
FEBS Lett., 1997, **405**, 157-162.
I.F. = 3.912

Lewalle,J.M., **Bajou,K.**, Desreux,J., Mareel,M., Dejana,E., Noel,A., Foidart,J.M.
Alteration of interendothelial adherens junctions following tumor cell- endothelial cell interaction in vitro.
Exp. Cell Res., 1997, **237**, 347-356.
I.F. = 4.712

Publication without peer review

Rakic,J.M., Maillard,C., Jost,M., **Bajou,K.**, Masson,V., Devy,L., Lambert,V., Foidart,J.M., Noel,A.
Role of plasminogen activator-plasmin system in tumor angiogenesis.
Cell Mol. Life Sci., 2003, **60**, 463-73.
I.F. =4.995

Bajou,K.

Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis.
Bull. Mem. Acad. R. Med. Belg., 2002, **157**, 313-318.

Bajou,K., Devy,L., Masson,V., Albert,V., Frankenne,F., Noel,A., Foidart,J.M.
Role of plasminogen activator inhibitor type 1 in tumor angiogenesis.
Therapie, 2001, **56**, 465-472.
I.F. =0.483

Noel,A., Albert,V., **Bajou,K.**, Devy,L., Frankenne,F., Maquoi,E., Masson,V., Sounni,N.E., Foidart,J.M.

New functions of stromal proteases and their inhibitors in tumor progression.
Surgical Oncology Clinics of North America, 2001, **10**, 417-432.

Frankenne,F., Noel,A., **Bajou,K.**, Sounni,N.E., Goffin,F., Masson,V., Munaut,C., Remacle,A., Foidart,J.M.

Molecular interaction involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy.
Emerging Therapeutic Targets, 1999, **3**, 469-481.

Noel,A., Gilles,C., **Bajou,K.**, Devy,L., Kebers,F., Lewalle,J.M., Maquoi,E., Munaut,C., Remacle,A., Foidart,J.M.

Emerging roles for proteinases in cancer.
Invasion Metastasis, 1997, **17**, 221-239.

Michiels,C., Arnould,T., Janssens,D., **Bajou,K.**, Geron,I., Remacle,J.

Interactions between endothelial cells and smooth muscle cells after their activation by hypoxia. A possible etiology for venous disease.
Int. Angiol., 1996, **15**, 124-130.
I.F. =0.709

Michiels,C., Arnould,T., Janssens,D., **Bajou,K.**, Remacle,J.

Le développement des veines variqueuses: rôle-clé de l'hypoxie et des cellules endothéliales.
Phlebologie, 1995, **48**, 203-206.
I.F. =0.657

Michiels,C., Arnould,T., Janssens,D., **Bajou,K.**, Geron,I., Remacle,J.

Interaction entre les cellules endothéliales et les cellules musculaires lisses après activation par l'hypoxie. Une étiologie possible de maladie veineuse.
Phlebologie, 1995, **48**, 141-149.
I.F. =0.657

Publication in conference book

Jost, M., Maillard, C., Lambert, V., Tjwa, M., Blaise, P., Lecomte, J., **Bajou, K.**, Blacher, S., Motte, P., Humblet, C., Defresne, M.P., Thiry, M., Frankenne, F., Gothot, A., Carmeliet, P., Rakic, J.M., Foidart J.M. and Noel, A.

Plasminogen activator inhibitor type I (PAI-1) controls bone marrow-dependent and independent vascularization.
Acta Clinica Belgica, 2006, **61**, 87.

De Groot, F.M.H., Devy, L., Blacher, S., Hajitou, A., **Bajou, K.**, Loos, W.J., de Bruijn, P., Scheeren, W., Foidart, J.M., Noel, A.C.

Antitumor doxorubicin prodrugs that contain (elongated) self-elimination spacers are specifically activated by tumor-associated plasmin and reduce tumor growth and angiogenesis without systemic toxicity.

American Chemical Society, 2002, **224**, U21-U22.

Noel, A., **Bajou, K.**, Masson, V., Devy, L., Frankenhe, F., Rakic, J.M., Lambert, V., Carmeliet, P., Foidart, J.M.

Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. *Fibrinolysis Proteol.*, 1999, **13**, 220-225

ORAL PRESENTATION IN MEETING WITH SCIENTIFIC COMMITTEES.

Bajou, K.

Targeting Plasminogen Activator Inhibitor-1 using 16K fragment of human prolactin.

International Conference on Advances in Biotechnology, July, 10-12, 2017, Dubai, United Arab Emirate.

Bajou, K.

Anti-angiogenic function of 16K Prolactin requires Plasminogen Activator Inhibitor-1 expression.

4th Biotechnology Word congress, February 15th -18th, 2016, Sharjah, United Arab Emirate.

Bajou, K.

Plasminogen activator inhibitor-1 between bench and clinic.

1st Annual UAE Biotechnology Students' Research & Innovation Conference, Dec. 15th & 16th, 2015, Sharjah, United Arab Emirate.

Bajou, K., Herkenne, S., Thijssen, V.L., D'Amico, S., Srahna, M., Carabin, J.Y., Gils, A., Declerck, P.J., Griffioen, A.W., Martial, J.A. and Struman, I.

PAI-1 mediates antiangiogenic and fibrinolytic actions of prolactin/growth hormone 16-14K fragments.

GIGA-Day meeting, January 31, 2011, Liège, Belgium.

Bajou, K., Peng, W., Walter, E.I., Noel, A., DeClerck, Y.A.

Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.

5th International Symposium on Serpin Biology, Structure and Function, July 12-16, 2008, Leuven, Belgium.

Bajou, K., Walter, E.I., Peng, W., Decklerck, P., Noel, A., Foidart, J.M., DeClerck, Y.A.

Proangiogenic fuction of plasminogen activator inhibitor-1 (PAI-1) in neuroblastoma angiogenesis: PAI-1 protects endothelial cells from FasL induced apoptosis.

Advance in Neuroblastoma Research, May 17-20, 2006, Los Angeles, CA.

Bajou,K., Walter,E.I., Peng, W., DeClerck,P., Foidart,J.M., Noel, A., DeClerck, Y.A.
Plasminogen Activator Inhibitor-1 promotes neuroblastoma progression and protects endothelial cells from apoptosis.

American Association for Cancer Research, 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.

Bajou,K., Laug,W.E., Peng,H., Foidart,J.M., Noel,A., DeClerck,Y.A.

Plasminogen Activator Inhibitor-1 promotes angiogenesis in neuroblastoma by protecting endothelial cells from apoptosis.

Gorgon Research Conferences, Plasminogen Activation and Extracellular Proteolysis, February 8-13, 2004, Ventura, CA.

Bajou,K., Masson,V., Albert,V., Shmitt,P.M., Loskutoff,D., Collen,D., Carmeliet,P., Noel,A., Foidart, J.M.

PAI-1: a key regulator of tumoral angiogenesis.

8th Euregional Oncology Meeting, April 19, 2001, Maastricht, Nederland.

BAJOU, K., MASSON, V., GERARD, R.D., DEVY, L., BRUNNER, N., DANO, K., FUSENIG, N.E., CARMELIET, P., COLLEN, D., FOIDART, J.M. AND NOËL, A.

Plasminogen activator inhibitor-1 is essential for cancer invasion and vascularization through its anti-proteolytic activity. Poster and oral presentation.

Belgian Association for Cancer Research Meeting, Gent (Belgium), January 29, 2000

BAJOU, K., NOEL, A., GERARD, R., MASSON, V., BRUNNER, N., HOLST-HANSEN, C., SKOBE, M., FUSENIG, N., CARMELIET, P., COLLEN, D. & FOIDART, J.M.

Rôle des protéase à sérine et leur inhibiteur dans l'invasion et l'angiogenèse tumorale.

Séminaire de la recherche (Televie) Brussels (Belgium) : Mars 16, 1999.

Bajou,K., Noël,A., Gerard,R., Masson,V., Holst-Hansen,C., Fusenig,N., Carmeliet,P., Collen,D., Foidart,J.M.

Absence of host plasminogen activator inhibitor-1 prevents cancer invasion.

Belgian Association for Cancer Research Meeting, January 24, 1998, Brussels, Belgium.

ABSTRACTS IN SCIENTIFIC MEETING.

HERKENNE,S., PAQUES,C., NIVELLES,O., **BAJOU,K.**, MARTIAL,J.A., NGUYEN,N.Q.N. AND STRUMAN I,

VEGF-induced angiogenesis requires internalization of the VEGFR2/uPAR/ β 1 integrin/ LRP-1 complexes.

Giga Day, University of Liège, Belgium, January 28, 2013

BOVY,N., BLOMME,B., FRERES,P., CARNET,O., **BAJOU,K.**, THIRY,M., MARTIAL,J.A., COLLIGNON,J., JÉRUSALEM,G., BOURS,V., TABRUYN,S.P., STRUMAN,I.

The Intercellular Transfer of Endothelial-Circulating-MiR-503 Inhibits Tumor Growth

Giga Day, University of Liège, Belgium, January 28, 2013

HERKENNE,S., **BAJOU, K.**, NGUYEN,N.Q.N., MARTIAL,J.A. AND STRUMAN,I.

PAI-1/uPA/uPAR complex mediates the antiangiogenic properties of 16K Prolactin.

Gordon research Conference, Toscane, Italy, Augustus 2012

HERKENNE,S., **BAJOU,K.**, NGUYEN,N.Q.N., MARTIAL,J.A. AND STRUMAN,I.

Implication of the PAI-1/uPA/uPAR signalosome in the antiangiogenic actions of 16K hPRL

Giga Day, University of Liège, Belgium, May 4, 2012

HERKENNE,S., ANTOINE,D.A., **BAJOU,K.**, NGUYEN,N.Q.N., MARTIAL,J.A. AND STRUMAN,I.

Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic actions of 16K hPRL

Biomedica, Liège, Belgium, April 18-19, 2012

HERKENNE,S., ANTOINE,D.A., **BAJOU,K.**, D'AMICO, S., NGUYEN,N.Q.N., MARTIAL,J.A. AND STRUMAN, I.

Implication of the PAI-1/uPA/uPAR complex in the antiangiogenic effects of 16K hPRL

GIGA-Cancer Day, University of Liège, Belgium, May 20, 2011.

HERKENNE,S., **BAJOU,K.**, D'AMICO,S., NGUYEN,N.Q.N., MARTIAL,J.A. AND STRUMAN,I.

Implication of the PAI-1/uPA/uPAR complex in the effects of the antiangiogenic factor 16K hPRL.

Giga Day, University of Liège, Belgium, May 20, 2011.

HERKENNE,S., **BAJOU,K.**, D'AMICO,S., MARTIAL,J.A. AND STRUMAN,I.

Implication of the PAI-1/uPA/uPAR complex in the angiostatic properties of 16K PRL and 14K GH

GIGA-Cancer Day. University of Liège, Belgium, May 21, 2010.

KINET, V., NGUYEN, N.Q.N., SABATEL, C. **BAJOU, K.**, BLACHER, S., NOEL, A., MARTIAL, J.A., STRUMAN, I.

Evaluation of the antitumor activity of 16K prolactin

Keystone symposia: angiogenesis and lymphangiogenesis in cancer, Silverthorne, CO, January 6-11, 2009

BAJOU, K., WALTER, L., PENG, W., DECLERCK, P., NOEL, A., FOIDART, J.M. AND DECLERCK, Y.A.

Solubilization of FasL by plasmin in the absence of plasminogen activator inhibitor-1 (PAI-1) induces endothelial cell apoptosis.

American Association for Cancer Research, 97th Annual Meeting, Washington, DC, April 1-5, 2006.

JOST M, LAMBERT V, MAILLARD C, TJWA M, **BAJOU K**, BLACHER S, BLAISE P, CARMELIET P, RAKIC JM, FOIDART JM & NOEL A.

Unexpected Differences In The Cellular Mechanisms Involved In Two Pathological Processes Of Vascularization Mediated By Plasminogen Activator Inhibitor Type I.

International Conference on Protease Inhibitors (ICPI), Quebec City, Canada: October 15-19, 2005.

JOST M, MAILLARD C, **BAJOU K**, VAN OVERSTRAETEN-SCHLÖGEL N, GOTHOT A, THIRY M, TWJA M, CARMELIET P, HUMBLET CH, DEFRESNE MP, FOIDART JM & NOEL A.

Mécanismes cellulaires impliqués au cours de la vascularisation tumorale dans un modèle de transplantation de kératinocytes tumoraux.

GRRC Strasbourg, France, 21-22 avril 2005.

BAJOU, K., WALTER, L., PENG, W., DECLERCK, P., FOIDART, J.M., NOEL, A. AND DECLERCK, Y.A.

Plasminogen Activator Inhibitor-1 promotes neuroblastoma progression and protects endothelial cells from apoptosis.

American Association for Cancer Research, 96th Annual Meeting, Anaheim, CA : April 16-20, 2005.

MAILLARD C, JOST M, HOUARD X, LEJEUNE A, RØMER MU, BRUNNER N, MUNAUT C, **BAJOU K**, MELEN L, DANO K, CARMELIET P, FUSENIG NE, FOIDART JM & NOEL A.

Host Plasminogen Activator Inhibitor-1 (PAI-1) promotes human skin carcinoma progression in a stage-dependent manner.

GRRC Strasbourg, France, April 21-22, 2005.

MAILLARD C, JOST M, HOUARD X, LEJEUNE A, RØMER MU, BRUNNER N, MUNAUT C, **BAJOU K**, MELEN L, DANO K, CARMELIET P, FUSENIG NE, FOIDART JM, & NOEL A. Host Plasminogen Activator Inhibitor-1 (PAI-1) promotes human skin carcinoma progression in a stage-dependent manner

Belgian Society for Cell Biology, Liège, Belgium, 16 octobre 2004,

BAJOU K, LAUG W.E., PENG W., MAILLARD C., FOIDART J.M., NOEL A. AND DECLERCK Y.A.

Absence of plasminogen activator inhibitor-1 inhibits angiogenesis and progression in neuroblastoma.

Advance in Neuroblastoma Research, Genoa (Italy): June 16-19, 2004

BAJOU K, MAILLARD C, JOST M, LIJNEN RH, GILS A, DECLERCK P, CARMELIET P, FOIDART JM & NOEL A. Host-derived Plasminogen Activator Inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.

BSCDB Spring Meeting 2004 "Functional Genomics in Development", Leuven, Belgium: 7-8 may 2004.

BAJOU K, MAILLARD C, JOST M, LIJNEN RH, GILS A, DECLERCK P, CARMELIET P, FOIDART JM & NOEL A. Host-derived Plasminogen Activator Inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.

BIOLOGIE ET PATHOLOGIE DU COEUR ET DES VAISSEAUX, La Baule (France): 22-23 avril 2004

BAJOU K., LAUG W.E., PENG H., FOIDART J.M., NOEL A. AND DECLERCK Y. Plasminogen Activator Inhibitor-1 promotes angiogenesis in neuroblastoma by protecting endothelial cells from apoptosis. Poster and Oral-presentation

Gorgon Research Conferences, Plasminogen Activation and Extracellular Proteolysis, Ventura, CA: February 8-13, 2004.

MAILLARD C, JOST M, **BAJOU K**, ROMER N, BRUNNER N, FOIDART JM & NOEL A. Pro-angiogenic function of PAI-1 in human tumors.

Belgian Association for Cancer Research. Annual Meeting 2004: "Genomics and Proteomics in Cancer", ULg (Liège): 24 janvier 2004.

MAILLARD C, JOST M, **BAJOU K**, ROMER N, BRUNNER N, FOIDART JM & NOEL A. Pro-angiogenic function of PAI-1 in human tumors.

Autumn Meeting de la Société Belge de Biologie Cellulaire et du Développement: "STEM CELL BIOLOGY", Faculté de Médecine UCL Bruxelles : 13 septembre 2003.

NOEL A, JOST M, **BAJOU K**, MAILLARD C, DEVY L, de GROOT F & FOIDART JM. Plasminogen activator inhibitor PAI-1 as a regulator of urokinase in angiogenesis. Présentation orale.

XIX Congress of the Isth and 49th Annual SSC Meeting, Birmingham (UK): 12-18 juillet 2003.

JOST M, LAMBERT V, MAILLARD C, MASSON V, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo models of pathological angiogenesis.

10th Euregional Oncology Meeting, University Hospital Maastricht (Nederland): 26 juin 2003.

JOST M, LAMBERT V, MAILLARD C, MASSON V, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo models of pathological angiogenesis.

Spring Meeting of the Belgian Society for Cell and Developmental Biology on "Endocytosis and Signalling", Bruxelles, Belgium, 16-17 mai 2003.

JOST M, LAMBERT V, MAILLARD C, MASSON V, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo models of pathological angiogenesis.

BIOFORUM 2003 - A one day meeting at the University of Liège between Bio-industries and young Life Sciences researchers, Liège, Belgium, 9 May 2003.

JOST M, LAMBERT V, MAILLARD C, MASSON V, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo models of pathological angiogenesis.

AP-Cancer Meeting, Ghent, (Belgium), 25 April, 2003

HAJITOU A, GRIGNET-DEBRUS C, DEVY D, DEROANNE CF, **BAJOU K**, BLACHER S, FONG T, CHIANG Y, FOIDART JM & NOEL A.

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.

13th Annual Meeting of the European Society of Gynaecological Oncology (E.S.G.O.), Bruxelles, Belgium, 6-10 April 2003.

JOST M, LAMBERT V, MAILLARD C, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo model of pathological angiogenesis.

13th Annual Meeting of the European Society of Gynaecological Oncology (E.S.G.O.), Bruxelles: 6-10 April 2003.

JOST M, LAMBERT V, MAILLARD C, **BAJOU K**, HUMBLET C, DEFRESNE MP, RAKIC JM, FOIDART JM & NOEL A.

Distinct implication of bone marrow stem cells in two in vivo models of pathological angiogenesis. Poster and oral presentation.

Annual Meeting 2003 of the A.B.E.C. "Signalling pathways in malignancy", Leuven : 18 janvier 2003.

LAMBERT V, MUNAUT C, **BAJOU K**, CARMELIET P, GERARD RD, DECLERCK PJ, GILS A, CLAES C, FOIDART JM, RAKIC JM & NOEL A.

Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I.

2nd Meeting of the InterUniversity Attraction Poles (IUAP), Leuven: 15 octobre 2002.

LAMBERT V, MUNAUT C, **BAJOU K**, PEYROLLIER K, ALVAREZ-GONZALEZ ML, CARMELIET P, FOIDART JM, NOEL A & RAKIC JM.

Mice lacking uPA, tPA or Plasminogen genes are resistant to experimental choroidal neovascularization.

2nd Meeting of the InterUniversity Attraction Poles (IUAP), Leuven: 15 octobre 2002.

HAJITOU A, GRIGNET-DEBRUS C, DEVY L, BERNDT S, BLACHER S, DEROANNE CF, **BAJOU K**, FONG T, CHIANG Y, FOIDART JM & NOEL A.

The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells.

2nd Meeting of the InterUniversity Attraction Poles (IUAP), Leuven: 15 octobre 2002.

BLACHER, S., DEVY, L., **BAJOU, K.**, BONJEAN, K., HEYMANS, O., NOEL, A., CASTRONOVO, V. and FOIDART, J.M.

Image analysis quantification of angiogenesis.

Belgian Society for Cell Biology. Liège (Belgique) : April 21, 2001.

MASSON, V., DEVY, L., **BAJOU, K.**, MUNAUT, C., RIO, M.C., WERB, Z., NOEL, A., FOIDART, J.M.

Role of gelatinase B, stromelysin-1 and -3 in tumor invasion and angiogenesis. Poster.

Belgian Society for Cell Biology. Liège (Belgique) : April 21, 2001.

MUNAUT, C., LAMBERT, V., **BAJOU, K.**, DEVY, L., MASSON, V., RAKIC, J.M., DESSY-DOIZE, C., NOEL, A. and FOIDART, J.M.

In vivo detection of MMP-9 promoter activity in transgenic mice.

Belgian Society for Cell Biology. Liège (Belgique) : April 21, 2001.

DEVY, L., BLACHER, S., GRIGNET-DEBRUS, C., **BAJOU, K.**, ROLAND, G., MASSON, V., GILS, A., CARMELIET, P., DECLERCK, P., NOEL, A., FOIDART, J.M.

The pro-or anti-angiogenic effect of plasminogen activator inhibitor PAI-1 is dose-dependent.

Belgian Society for Cell Biology. Liège (Belgique) : April 21, 2001.

DEVY, L., BLACHER, S., GRIGNET-DEBRUS, C., **BAJOU, K.**, ROLAND, G., MASSON, V., GILS, A., CARMELIET, P., DECLERCK, P., NOEL, A., FOIDART, J.M.

The pro-or anti-angiogenic effect of plasminogen activator inhibitor PAI-1 is dose-dependent.

8th Euregional Oncology Meeting. Maastricht (Hollande) :April 19, 2001.

LAMBERT V, MUNAUT C, NOEL A, FRANKENNE F, **BAJOU K**, GERARD R, CARMELIET P, FOIDART JM & RAKIC JM.

Influence of Plasminogen Activator Inhibitor Type 1 on Choroidal Neovascularization.

NCI-EORTC-AACR symposium on new drugs in cancer therapy, Amsterdam (Hollande) : 7-10 novembre 2000

DEVY, L., BLACHER, S., **BAJOU, K.**, ROLAND, G., BURBRIDGE, M., CARMELIET, P., DECLERCK, P., NOEL, A., FOIDART, J.M.

The plasminogen activator inhibitor PAI-1 controls neovessel formation in the mice aortic ring assay.

American Association for Cancer Research, angiogenesis and cancer: from basic mechanisms to therapeutic applications, Michigan (USA) : October 11-15, 2000.

BAJOU, K., MASSON, V., GERARD, R.D., DEVY, L., BRUNNER, N., DANO, K., FUSENIG, N.E., CARMELIET, P., COLLEN, D., FOIDART, J.M. AND NOËL, A.

Plasminogen activator inhibitor-1 is essential for cancer invasion and vascularization through its anti-proteolytic activity.

First North sea Conference on Thrombosis and Haemostasis and 46th Scientific and Standardization Committee Meeting of the ISTH, Maastricht, June 12-17, 2000.

MASSON V, **BAJOU K**, NOEL A & FOIDART JM.

Matrix metalloproteinases and their inhibitors in tumour invasion and angiogenesis.

International Symposium "Women's Health 2000", Anvers: May 11-13, 2000.

BAJOU, K., MASSON, V., SCHMID, P., GERARD, R.D., ALBERT, V., BRUNNER, N., DANO, K., FUSENIG, N.E., LOSKUTOFF, D.J., COLLEN, D., CARMELIET, P., FOIDART, J.M. AND NOËL, A.

The angiogenic activity of the plasminogen activator inhibitor PAI-1 does not depend on its interaction with vitronectin : implications for therapeutic inhibition of tumor angiogenesis.

Belgian Society for Cell Biology. Brussels (Belgique) : Mars 18, 2000.

Cell Biology International, 25(4), 378, 2001.

DEVY, L., NOEL, A., BLACHER, S., **BAJOU, K.**, BURBRIDGE, M., CARMELIET, P., FOIDART, J.M.

The mouse aortic ring assay : a new approach to the molecular genetics of angiogenesis.

Belgian Society for Cell Biology. Brussels (Belgique) : Mars 18, 2000.

Cell Biology International, 25(4), 382, 2001.

BAJOU, K., MASSON, V., GERARD, R.D., DEVY, L., BRUNNER, N., DANO, K., FUSENIG, N.E., CARMELIET, P., COLLEN, D., FOIDART, J.M. AND NOËL, A.

Plasminogen activator inhibitor-1 is essential for cancer invasion and vascularization through its anti-proteolytic activity.

Gorgon Research Conferences, Thrombolysis, Ventura, CA: February 6-11, 2000.

BAJOU, K., MASSON, V., GERARD, R.D., DEVY, L., BRUNNER, N., DANO, K., FUSENIG, N.E., CARMELIET, P., COLLEN, D., FOIDART, J.M. AND NOËL, A.

Plasminogen activator inhibitor-1 is essential for cancer invasion and vascularization through its anti-proteolytic activity. Poster and oral presentation.

Belgian Association for Cancer Research Meeting, Gent, January 29, 2000

DEVY, L., NOEL, A., **BAJOU, K.**, BURBRIDGE, M., CARMELIET, P., FOIDART, J.M.
The mouse aortic ring assay: a new approach to the molecular genetics of angiogenesis.
Belgian Association for Cancer Research Meeting, Gent, January 29, 2000.

MASSON V, **BAJOU K**, NOEL A & FOIDART JM. Rôle des métalloprotéases, de leurs inhibiteurs et de leurs activateurs dans l'invasion et l'angiogenèse tumorales.
3rd Congress of the European Society of Gynecology, Bruges: 23-30 octobre 1999.

BAJOU, K., MASSON, V., FUSENIG, N., CARMELIET, P., COLLEN, D., NOEL, A & FOIDART, J.M.

In vivo tumor invasion occurs in the absence of host uPA, TPA, uPAR and plasminogen but is impaired in the absence of host PAI-1.

Belgian Society for Cell Biology. Gent (Belgique) : Mars 6, 1999.

BAJOU, K., NOEL, A., GERARD, R., MASSON, V., BRUNNER, N., HOLST-HANSEN, C., SKOBE, M., FUSENIG, N., CARMELIET, P., COLLEN, D. & FOIDART, J.M.

Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularisation.

Belgian Society for Cell Biology. Namur (Belgique) : October 17, 1998.

LEWALLE, J.M., **BAJOU, K.**, BARAMOVA, E. & FOIDART, J.M.

Tumor cell-derived serine proteases participate to pro-MMP-2 activation by endothelial cells in vitro.

Belgian Society for Cell Biology. Namur (Belgique) : October 17, 1998.

BAJOU, K., NOËL, A., GERARD, R., MASSON, V., HOLST-HANSEN, C., FUSENIG, N., CARMELIET, P., COLLEN, D., & FOIDART, J.M.

Absence of host plasminogen activator inhibitor-1 prevents cancer invasion. Poster and oral presentation.

Belgian Association for Cancer Research Meeting, Brussels, January 24, 1998

LEWALLE, J.M., **BAJOU, K.**, BARAMOVA, E. & FOIDART, J.M.

Tumor cell-derived serine proteases participate to pro-MMP-2 activation by endothelial cells in vitro.

Belgian Association for Cancer Research Meeting, Brussels, January 24, 1998

BAJOU, K., NOËL, A., GERARD, R., MASSON, V., HOLST-HANSEN, C., FUSENIG, N., CARMELIET, P., COLLEN, D., & FOIDART, J.M.

Absence of host plasminogen activator inhibitor-1 prevents cancer invasion.

5th Euregional Oncology Meeting, Maastricht, January 23, 1998.

LEWALLE, J.M., **BAJOU, K.**, BARAMOVA, E. & FOIDART, J.M.

Tumor cell-derived serine proteases participate to pro-MMP-2 activation by endothelial cells in vitro.

5th Euregional Oncology Meeting, Maastricht, January 23, 1998.

BAJOU, K., NOEL, A., GERARD, R., MASSON, V., BRUNNER, N., HOLST-HANSEN, C., FUSENIG, N., CARMELIET, P., COLLEN, D. & FOIDART, J.M.
Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularisation.
American Association for Cancer Research and Acta Pathologica Microbiologica et Immunologica Scandinavica. Proteases and Protease Inhibitors in Cancer. Nyborg (Danemark) : Jun 14-18, 1998.

BAJOU, K., NOEL, A., GERARD, R., MASSON, V. BRUNNER, N., HOLST-HANSEN, C., FUSENIG, N., CARMELIET, P., COLLEN, D. & FOIDART, J.M.
Absence of host plasminogen activator inhibitor-1 prevents cancer invasion.
5th International Meeting. European Vascular Biology Association. Vaalbeek, Leuven (Belgique): May 8-10, 1998.

BAJOU, K., NOEL, A., GERARD, R., MASSON, V., BRUNNER, N., HOLST-HANSEN, C., FUSENIG, N., CARMELIET, P., COLLEN, D. & FOIDART, J.M.
Absence of host plasminogen activator inhibitor-1 prevents cancer invasion.
89th Annual Meeting of the American Association for Cancer Research. New Orleans, LA (USA) : 28 Mars – April 1, 1998..

BAJOU, K., LEWALLE, J.M., RODRIGUEZ, C., NOEL, A. & FOIDART, J.M.
Modification of plasminogen activator systems during interactions between human umbilical vein endothelial cells and breast adenocarcinoma cells.
4th Euregional Oncology Meeting. Maastricht (Hollande) : January 17, 1997.

BARAMOVA, E.N., NOEL, A., **BAJOU, K.**, L'HOIR, C., REMACLE, A. & FOIDART J.M.
Involvement of Plasminogen Activator (PA)/plasmin system in the second step of pro-MMP-2 activation.
4th Euregional Oncology Meeting. Maastricht (Hollande) : January 17, 1997.

LEWALLE, J.M., **BAJOU, K.**, DESREUX, J., MAREEL, M., DEJANA, E., NOEL, A. & FOIDART, J.M.
Alteration of interendothelial adherens junctions following tumor cell - endothelial cell interaction.
4th Euregional Oncology Meeting. Maastricht (Hollande) : January 17, 1997.

LEWALLE, J.M., CATALDO, D., **BAJOU, K.**, LAMBERT C.A. & FOIDART, J.M.
Endothelial cell intracellular Ca⁺⁺ concentration mediates human breast adenocarcinoma cell transendothelial migration.
4th Euregional Oncology Meeting, Maastricht, January 17, 1997.

BAJOU, K., LEWALLE, J.M., RODRIGUEZ, C., NOEL, A. & FOIDART, J.M.
Modification of plasminogen activator systems during interactions between human umbilical vein endothelial cells and breast adenocarcinoma cells.
Eulep Symposium. Angiogenesis in Wound Healing, Post-Irradiation Scarring, and Cancer. Spa - Sol Cress (Belgique) : October 8, 1996.

BAJOU, K., LEWALLE, J.M., RODRIGUEZ, C., NOEL, A. & FOIDART, J.M.
Modification of plasminogen activator systems during interactions between human umbilical vein endothelial cells and breast adenocarcinoma cells.
XVth FECTS Meeting, Munich, August 4-9, 1996.

LEWALLE, J.M., BAJOU, K., DESREUX, J., MAREEL, M., DEJANA, E., NOEL, A. & FOIDART, J.M.
Alteration of interendothelial adherens junctions following tumor cell - endothelial cell interactions.
Clin. and Exp. Metast., vol 14, suppl 1, 21, 1996.

LEWALLE, J.M., BAJOU, K., DESREUX, J., DEJENA, E., MAREEL, M., NOEL, A. & FOIDART, J.M.
Altération des jonctions adhérentes interendothéliales suite aux interactions avec les cellules tumorales : une étape précoce de l'extravasation.
3ème journée de la Recherche en Cancérologie à l'ULg. Liège, May 9, 1996.

BAJOU, K., LEWALLE, J.M., RODRIGUEZ, C., NOEL, A. & FOIDART, J.M.
Modification des activateurs du plasminogène au cours des interactions des cellules endothéliales et des cellules tumorales mammaires humaines.
3ème journée de la Recherche en Cancérologie à l'ULg. Liège, May 9, 1996.

BAJOU, K., MICHIELS, C., ARNOULD, T., REMACLE, J.
Hypoxic endothelial cell-induced phenotypic modulation of smooth muscle cells.
Cell Biol. Int., 17 (2), 1994.